Jasper Therapeutics, Inc. JSPR
Jasper Therapeutics, Inc. (Nasdaq: JSPR) is a cardio-renal-metabolic drug developer. Its lead program, KP-104 (vensobafusp alfa), is in Phase 2 for PNH and rare renal indications (IgA nephropathy, C3 glomerulopathy; Phase 2 basket trial). Its next catalyst on record is KP-104: Interim data from Stage 1 of Phase 2 basket trial (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: KP-104 — Interim data from Stage 1 of Phase 2 basket trial (Q4 2026). 8 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| KP-104 (vensobafusp alfa) | Rare renal disorders (IgAN, C3G, potential FSGS); prior positive data in treatment-naive PNH | protein/peptide | Phase 2 |
| briquilimab | Chronic spontaneous urticaria (Phase 1b/2a BEACON; Phase 2b/3 planned) | antibody | Phase 2 |
| briquilimab | Chronic inducible urticaria (Phase 1b/2a SPOTLIGHT) | antibody | Phase 2 |
| briquilimab | SCID conditioning (Phase 1/2 data; pre-BLA meeting being sought; orphan, fast track, rare pediatric designations) | antibody | Phase 2 |
| KP-701 | Autoantibody-mediated disorders (anti-CD79BxCD32B) | antibody | Pre-clinical |
| Long-acting complement-targeted biologics | Autoimmune inflammatory disorders | biologic-other | Pre-clinical |
Recent results and decisions
- Jan 8, 2026positive BEACON cohort 9.1 (n=6, 240mg then 180mg Q8W): 83% (5/6) complete response at week 3, 67% (4/6) CR at week 12, mean 31-point UAS7 reduction at week 12.
83% (5 of 6) of patients achieved a CR at week 3 after initial 240mg loading dose
Filing - Dec 2, 2025positive Phase 1b/2a ETESIAN (n=17, single 180mg dose) showed briquilimab mitigated allergen-challenge FEV1 response and airway hyperresponsiveness vs placebo with a favorable safety profile; study terminated early for administrative reasons.
Robust and sustained impact of mast - cell depletion on asthmatic response at 6 and 12 weeks
Filing - Dec 2, 2025mixed Internal investigation of anomalous BEACON cohort 8/9 non-response found no drug product or study conduct issues; KOL panel judged 9 of 10 non-responders likely did not have CSU, and redosing with a new lot did not change outcomes in 8 of 9 patients.
Unexpected efficacy results appear to largely be the result of patient selection
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.